Review Series 10.1172/JCI95146

Senescent cells: a therapeutic target for cardiovascular disease

Bennett G. Childs,1 Hu Li,2 and Jan M. van Deursen1,3

1Department of Biochemistry and Molecular Biology,

2Department of Molecular Pharmacology and Experimental Therapeutics, and

3Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Address correspondence to: Jan M. van Deursen, 200 1st St. SW, Rochester MN 55902, USA. Phone: 507.284.8417; Email: vandeursen.jan@mayo.edu.

Find articles by Childs, B. in: JCI | PubMed | Google Scholar

1Department of Biochemistry and Molecular Biology,

2Department of Molecular Pharmacology and Experimental Therapeutics, and

3Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Address correspondence to: Jan M. van Deursen, 200 1st St. SW, Rochester MN 55902, USA. Phone: 507.284.8417; Email: vandeursen.jan@mayo.edu.

Find articles by Li, H. in: JCI | PubMed | Google Scholar

1Department of Biochemistry and Molecular Biology,

2Department of Molecular Pharmacology and Experimental Therapeutics, and

3Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Address correspondence to: Jan M. van Deursen, 200 1st St. SW, Rochester MN 55902, USA. Phone: 507.284.8417; Email: vandeursen.jan@mayo.edu.

Find articles by van Deursen, J. in: JCI | PubMed | Google Scholar

First published April 2, 2018 - More info

Published in Volume 128, Issue 4 (April 2, 2018)
J Clin Invest. 2018;128(4):1217–1228. https://doi.org/10.1172/JCI95146.
Copyright © 2018, American Society for Clinical Investigation

Published April 2, 2018

Cellular senescence, a major tumor-suppressive cell fate, has emerged from humble beginnings as an in vitro phenomenon into recognition as a fundamental mechanism of aging. In the process, senescent cells have attracted attention as a therapeutic target for age-related diseases, including cardiovascular disease (CVD), the leading cause of morbidity and mortality in the elderly. Given the aging global population and the inadequacy of current medical management, attenuating the health care burden of CVD would be transformative to clinical practice. Here, we review the evidence that cellular senescence drives CVD in a bimodal fashion by both priming the aged cardiovascular system for disease and driving established disease forward. Hence, the growing field of senotherapy (neutralizing senescent cells for therapeutic benefit) is poised to contribute to both prevention and treatment of CVD.

Preview pages

Reset
Page preview
1218 Page 1217 Back

Continue reading with a subscription.

A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.

Already subscribed?

Click here to sign into your account.

Don't have a subscription?

Please select one of the subscription options, which includes a low-cost option just for this article.

At an institution or library?

If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).

Problems?

Please try these troubleshooting tips.

  • Purchase this article
  • $10
  • Purchasing this article will give you full access for the calendar year.
  • Purchase article
  • Purchase Site Pass
  • $25
  • This will give you access to every article on the site for 24 hours.
  • Order site pass
  • Online subscription
  • $95
  • Individual online subscriptions give you full online access for the calendar year.
  • Order Online
  • Print subscription
  • $795
  • Individual print subscriptions give you the print journal and full online access for the year.
  • Print + Online
  • JCI This Month subscription
  • $125
  • JCI This Month is a 16- to 20-page overview of the articles published each month
  • Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
  • *Price outside U.S. and Canada: $225.
  • JCI This Month + Online
Advertisement